Literature DB >> 26176980

Natural history of COPD: Focusing on change in FEV1.

Jørgen Vestbo1, Peter Lange2,3.   

Abstract

The natural history of chronic obstructive pulmonary disease (COPD) is usually described with a focus on change in forced expiratory volume in 1 s (FEV1 ) over time as this allows for exploration of risk factors for an accelerated decline-and thus of developing COPD. From epidemiological studies we have recognized important risk factors such as smoking, exposure to biomass and occupational exposures, but we have also learnt about features such as chronic bronchitis, airway hyper-responsiveness and asthma that seem to accelerate decline in FEV1 independent of exposures. In addition we are gradually beginning to better link early life events to subsequent risk of disease in adulthood. Although more complicated, our current understanding of COPD has come a long way from being a simple image of smoking leading to poor lungs.
© 2015 Asian Pacific Society of Respirology.

Entities:  

Keywords:  biomass; chronic obstructive pulmonary disease; risk factors; smoking; spirometry

Mesh:

Year:  2015        PMID: 26176980     DOI: 10.1111/resp.12589

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  11 in total

Review 1.  Evaluation of Individuals at Risk for COPD: Beyond the Scope of the Global Initiative for Chronic Obstructive Lung Disease.

Authors:  Julio D Antuni; Peter J Barnes
Journal:  Chronic Obstr Pulm Dis       Date:  2016-06-28

2.  Airway Epithelial Progenitors and the Natural History of Chronic Obstructive Pulmonary Disease.

Authors:  Renat Shaykhiev
Journal:  Am J Respir Crit Care Med       Date:  2018-04-01       Impact factor: 21.405

Review 3.  Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward.

Authors:  Fernando J Martinez; Alvar Agusti; Bartolome R Celli; MeiLan K Han; James P Allinson; Surya P Bhatt; Peter Calverley; Sanjay H Chotirmall; Badrul Chowdhury; Patrick Darken; Carla A Da Silva; Gavin Donaldson; Paul Dorinsky; Mark Dransfield; Rosa Faner; David M Halpin; Paul Jones; Jerry A Krishnan; Nicholas Locantore; Fernando D Martinez; Hana Mullerova; David Price; Klaus F Rabe; Colin Reisner; Dave Singh; Jørgen Vestbo; Claus F Vogelmeier; Robert A Wise; Ruth Tal-Singer; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2022-02-01       Impact factor: 21.405

4.  Machine Learning Prediction of Progression in Forced Expiratory Volume in 1 Second in the COPDGene® Study.

Authors:  Adel Boueiz; Zhonghui Xu; Yale Chang; Aria Masoomi; Andrew Gregory; Sharon M Lutz; Dandi Qiao; James D Crapo; Jennifer G Dy; Edwin K Silverman; Peter J Castaldi
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

5.  Declining Lung Function and Cardiovascular Risk: The ARIC Study.

Authors:  Odilson M Silvestre; Wilson Nadruz; Gabriela Querejeta Roca; Brian Claggett; Scott D Solomon; Maria C Mirabelli; Stephanie J London; Laura R Loehr; Amil M Shah
Journal:  J Am Coll Cardiol       Date:  2018-09-04       Impact factor: 24.094

Review 6.  Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.

Authors:  Eric Derom; Guy G Brusselle; Guy F Joos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-12-13

7.  Proteolytic biomarkers are related to prognosis in COPD- report from a population-based cohort.

Authors:  Robert Linder; Eva Rönmark; Jamshid Pourazar; Annelie F Behndig; Anders Blomberg; Anne Lindberg
Journal:  Respir Res       Date:  2018-04-12

8.  From COPD epidemiology to studies of pathophysiological disease mechanisms: challenges with regard to study design and recruitment process: Respiratory and Cardiovascular Effects in COPD (KOLIN).

Authors:  Anne Lindberg; Robert Linder; Helena Backman; Jonas Eriksson Ström; Andreas Frølich; Ulf Nilsson; Eva Rönmark; Viktor Johansson Strandkvist; Annelie F Behndig; Anders Blomberg
Journal:  Eur Clin Respir J       Date:  2017-12-17

9.  Statin use and lung cancer risk in chronic obstructive pulmonary disease patients: a population-based cohort study.

Authors:  Ajn Raymakers; D D Sin; M Sadatsafavi; J M FitzGerald; C A Marra; L D Lynd
Journal:  Respir Res       Date:  2020-05-19

10.  Contributions of burning incense on indoor air pollution levels and on the health status of patients with chronic obstructive pulmonary disease.

Authors:  Su-Er Guo; Miao-Ching Chi; Chieh-Mo Lin; Tsung-Ming Yang
Journal:  PeerJ       Date:  2020-08-31       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.